Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

NCT02687542 PHASE2 TERMINATED Results posted

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

Details

Lead sponsor	Pfizer
Phase	PHASE2
Status	TERMINATED
Enrolment	108
Start date	Thu Mar 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Nov 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Parkinson Disease

Interventions

• Placebo
• PF-06649751 low dose (1 mg QD)
• PF-06649751 middle dose 1 (3 mg QD)
• PF-06649751 middle dose 2 (7 mg QD)
• PF-06649751 high dose (15 mg QD)

Countries

France, Japan, Germany, Canada, United States, Spain